Cybin Inc. (NYSEAMERICAN:CYBN - Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 14,900,000 shares, an increase of 17.0% from the July 31st total of 12,740,000 shares. Approximately 2.1% of the shares of the stock are sold short. Based on an average trading volume of 4,880,000 shares, the short-interest ratio is presently 3.1 days.
Hedge Funds Weigh In On Cybin
A hedge fund recently bought a new stake in Cybin stock. Rathbones Group PLC bought a new stake in shares of Cybin Inc. (NYSEAMERICAN:CYBN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 65,381 shares of the company's stock, valued at approximately $26,000. 17.94% of the stock is currently owned by institutional investors and hedge funds.
Cybin Trading Down 0.5 %
NYSEAMERICAN:CYBN traded down $0.00 during mid-day trading on Monday, reaching $0.26. The company's stock had a trading volume of 6,510,200 shares, compared to its average volume of 4,898,840. Cybin has a twelve month low of $0.23 and a twelve month high of $0.74. The firm has a market cap of $104.77 million, a price-to-earnings ratio of -1.21 and a beta of 0.50.
Cybin (NYSEAMERICAN:CYBN - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Cybin will post -0.22 earnings per share for the current fiscal year.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Recommended Stories
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
